Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
News and updates for Alterity Therapeutics Limited (ATHE) center on its progress as a clinical stage biotechnology company developing disease modifying treatments for neurodegenerative diseases. The company’s announcements emphasize its initial focus on Parkinson’s disease and related disorders, particularly Multiple System Atrophy (MSA), and the development of its lead oral agent ATH434.
Investors and followers of ATHE can expect regular news about clinical trial milestones and data presentations. Alterity has reported positive results from its ATH434‑201 randomized, double‑blind, placebo‑controlled Phase 2 trial in MSA, as well as topline data from the ATH434‑202 open‑label Phase 2 trial in more advanced MSA. Company news often highlights analyses of UMSARS Part I activities of daily living scores, orthostatic hypotension symptom assessments, wearable sensor data, and neuroimaging and biomarker endpoints such as brain iron and the MSA Atrophy Index.
Alterity’s news flow also includes regulatory and designation updates, such as Fast Track Designation by the U.S. Food and Drug Administration and Orphan Drug Designation by the FDA and European Commission for ATH434 in MSA. Additional items cover participation in major neurology and movement disorder conferences, where the company presents new analyses, biomarker findings, and natural history study results, as well as appearances at healthcare and biotech investor events.
On this page, readers can follow announcements about capital raises, quarterly cash flow reports, and corporate presentations that describe Alterity’s cash position, development plans, and engagement with regulators. For those tracking ATHE, the news stream provides context on how the company is advancing ATH434 in MSA, refining its biomarker strategy, and interacting with the scientific and investment communities over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced findings from the bioMUSE study at the American Academy of Neurology Annual Meeting, showcasing wearable sensors' effectiveness in quantifying motor impairment in patients with Multiple System Atrophy (MSA). The analysis involved 17 participants and indicated a strong correlation between sensor parameters and traditional clinical assessments of motor impairment. This data is significant for future clinical trials, as wearable sensors will be integrated as secondary endpoints in the ongoing Phase 2 trial of ATH434. ATH434 aims to address neurodegeneration and has shown promise in preclinical studies. The ongoing research is pivotal for understanding MSA's progression and optimizing treatment methods.
Alterity Therapeutics (ATHE) has initiated its Phase 2 clinical trial for ATH434 in the UK, targeting Multiple System Atrophy (MSA), a rare neurodegenerative disorder. This trial is a randomized, double-blind, placebo-controlled study intended to evaluate ATH434's effects on neuroimaging and protein biomarkers. With the first UK participant dosed, the trial aims to enroll approximately 60 adults over 12 months, focusing on efficacy and safety. ATH434 has shown preclinical promise and is acknowledged with Orphan designation by the U.S. FDA and European Commission for MSA treatment, indicating significant therapeutic potential for this debilitating condition.
FAQ
What is the current stock price of Alterity Therapeutics (ATHE)?
What is the market cap of Alterity Therapeutics (ATHE)?
